Sai Life Sciences, a Hyderabad-based contract research, development and manufacturing (CRDMO) company, has reported results for July–September 2026, the second quarter of FY27. Both its contract research (CRO) and contract manufacturing (CDMO) businesses grew.
Key numbers
- Revenue ₹659 crore, up 23% from ₹537 crore a year earlier.
- EBITDA up 20% to ₹187 crore; margin slipped to 28% from 29%.
- Net profit up 17% to ₹98 crore.
- April–September: revenue ₹1,213 crore (up 17%), profit ₹172 crore (up 19%).
Expansion and the stock
The company spent ₹621 crore on expansion in the half-year and reiterated a full-year capex plan of ₹1,100–1,300 crore. DSIJ reports it has opened a new Process R&D block in Hyderabad. Management, led by MD and CEO Krishna Kanumuri, expects a stronger second half.
On Friday the shares rose about 10% on the NSE to a record ₹1,775. Business Standard said the previous high was ₹1,697, set on September 9.
